All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Medicinova Inc., of La Jolla, Calif., reported top-line results from the SPRINT-MS phase IIb trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis.